Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy

D. Ferone, R. Pivonello, D. J. Kwekkeboom, F. Gatto, P. Ameri, A. Colao, R. R. De Krijger, F. Minuto, S. W J Lamberts, P. M. Van Hagen, L. J. Hofland

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: [111In-DTPA-D-Phe1]-octreotide scintigraphy allows the visualization of SRIF receptor (SSR)-expressing tumors, including thymic tumors, and normal tissues. While the spleen is clearly visualized, the thymus is not depicted, although both contain SSR. Aim: We evaluated whether the heterogeneity, the type, and the amount of SSR might explain this contrasting finding. Materials, methods, and results: By ligand-binding the number of [125I-Tyr11]-SRIF-14 binding sites resulted comparable between the two tissues, whereas the number of [ 125I-Tyr3]-octreotide sites was significantly higher in the spleen (p2A mRNA in the spleen, whereas a significantly higher expression of SRIF and sst3 in the thymus. The highest density of sst2A in the spleen is in line with the in vivo uptake of [ 111In-DTPA-D-Phe1]-octreotide, which is considered a sst2-preferring ligand. The specificity is confirmed by the evidence that in vivo [111In-DT-PA-D-Phe1]-octreotide uptake can be abolished during chronic administration of "cold" octreotide. Immunohistochemistry confirmed a preferential expression of sst2A on microenvironmental cells and of sst3 on lymphoid cells. Conclusions: The heterogeneity of SSR expression and the higher SRIF content explain the lack of thymus visualization during scintigraphy, whereas thymic tumors, which do not express SRIF, are visualized. Apart from the affinity of the radioligand, also the efficacy of the internalization is crucial for the in vivo uptake, and both heterogeneity and SRIF content affect this process. These observations might have an important impact when interpretating in vivo visualization of SSR-positive lesions, and when treatment with novel SRIF analogs is considered.

Original languageEnglish
Pages (from-to)528-534
Number of pages7
JournalJournal of Endocrinological Investigation
Volume35
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Somatostatin Receptors
Octreotide
Radionuclide Imaging
Thymus Gland
Spleen
Thymus Neoplasms
Pentetic Acid
Ligands
Immunohistochemistry
Binding Sites
Lymphocytes
Messenger RNA
Neoplasms

Keywords

  • Receptor interaction
  • Somatostatin
  • Somatostatin receptors
  • Spleen
  • Thymus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus : Implications for the in vivo visualization during somatostatin receptor scintigraphy. / Ferone, D.; Pivonello, R.; Kwekkeboom, D. J.; Gatto, F.; Ameri, P.; Colao, A.; De Krijger, R. R.; Minuto, F.; Lamberts, S. W J; Van Hagen, P. M.; Hofland, L. J.

In: Journal of Endocrinological Investigation, Vol. 35, No. 5, 05.2012, p. 528-534.

Research output: Contribution to journalArticle

Ferone, D. ; Pivonello, R. ; Kwekkeboom, D. J. ; Gatto, F. ; Ameri, P. ; Colao, A. ; De Krijger, R. R. ; Minuto, F. ; Lamberts, S. W J ; Van Hagen, P. M. ; Hofland, L. J. / Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus : Implications for the in vivo visualization during somatostatin receptor scintigraphy. In: Journal of Endocrinological Investigation. 2012 ; Vol. 35, No. 5. pp. 528-534.
@article{1cb8710654f44ba29cebfa065f17cd54,
title = "Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy",
abstract = "Background: [111In-DTPA-D-Phe1]-octreotide scintigraphy allows the visualization of SRIF receptor (SSR)-expressing tumors, including thymic tumors, and normal tissues. While the spleen is clearly visualized, the thymus is not depicted, although both contain SSR. Aim: We evaluated whether the heterogeneity, the type, and the amount of SSR might explain this contrasting finding. Materials, methods, and results: By ligand-binding the number of [125I-Tyr11]-SRIF-14 binding sites resulted comparable between the two tissues, whereas the number of [ 125I-Tyr3]-octreotide sites was significantly higher in the spleen (p2A mRNA in the spleen, whereas a significantly higher expression of SRIF and sst3 in the thymus. The highest density of sst2A in the spleen is in line with the in vivo uptake of [ 111In-DTPA-D-Phe1]-octreotide, which is considered a sst2-preferring ligand. The specificity is confirmed by the evidence that in vivo [111In-DT-PA-D-Phe1]-octreotide uptake can be abolished during chronic administration of {"}cold{"} octreotide. Immunohistochemistry confirmed a preferential expression of sst2A on microenvironmental cells and of sst3 on lymphoid cells. Conclusions: The heterogeneity of SSR expression and the higher SRIF content explain the lack of thymus visualization during scintigraphy, whereas thymic tumors, which do not express SRIF, are visualized. Apart from the affinity of the radioligand, also the efficacy of the internalization is crucial for the in vivo uptake, and both heterogeneity and SRIF content affect this process. These observations might have an important impact when interpretating in vivo visualization of SSR-positive lesions, and when treatment with novel SRIF analogs is considered.",
keywords = "Receptor interaction, Somatostatin, Somatostatin receptors, Spleen, Thymus",
author = "D. Ferone and R. Pivonello and Kwekkeboom, {D. J.} and F. Gatto and P. Ameri and A. Colao and {De Krijger}, {R. R.} and F. Minuto and Lamberts, {S. W J} and {Van Hagen}, {P. M.} and Hofland, {L. J.}",
year = "2012",
month = "5",
doi = "10.3275/7871",
language = "English",
volume = "35",
pages = "528--534",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "5",

}

TY - JOUR

T1 - Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus

T2 - Implications for the in vivo visualization during somatostatin receptor scintigraphy

AU - Ferone, D.

AU - Pivonello, R.

AU - Kwekkeboom, D. J.

AU - Gatto, F.

AU - Ameri, P.

AU - Colao, A.

AU - De Krijger, R. R.

AU - Minuto, F.

AU - Lamberts, S. W J

AU - Van Hagen, P. M.

AU - Hofland, L. J.

PY - 2012/5

Y1 - 2012/5

N2 - Background: [111In-DTPA-D-Phe1]-octreotide scintigraphy allows the visualization of SRIF receptor (SSR)-expressing tumors, including thymic tumors, and normal tissues. While the spleen is clearly visualized, the thymus is not depicted, although both contain SSR. Aim: We evaluated whether the heterogeneity, the type, and the amount of SSR might explain this contrasting finding. Materials, methods, and results: By ligand-binding the number of [125I-Tyr11]-SRIF-14 binding sites resulted comparable between the two tissues, whereas the number of [ 125I-Tyr3]-octreotide sites was significantly higher in the spleen (p2A mRNA in the spleen, whereas a significantly higher expression of SRIF and sst3 in the thymus. The highest density of sst2A in the spleen is in line with the in vivo uptake of [ 111In-DTPA-D-Phe1]-octreotide, which is considered a sst2-preferring ligand. The specificity is confirmed by the evidence that in vivo [111In-DT-PA-D-Phe1]-octreotide uptake can be abolished during chronic administration of "cold" octreotide. Immunohistochemistry confirmed a preferential expression of sst2A on microenvironmental cells and of sst3 on lymphoid cells. Conclusions: The heterogeneity of SSR expression and the higher SRIF content explain the lack of thymus visualization during scintigraphy, whereas thymic tumors, which do not express SRIF, are visualized. Apart from the affinity of the radioligand, also the efficacy of the internalization is crucial for the in vivo uptake, and both heterogeneity and SRIF content affect this process. These observations might have an important impact when interpretating in vivo visualization of SSR-positive lesions, and when treatment with novel SRIF analogs is considered.

AB - Background: [111In-DTPA-D-Phe1]-octreotide scintigraphy allows the visualization of SRIF receptor (SSR)-expressing tumors, including thymic tumors, and normal tissues. While the spleen is clearly visualized, the thymus is not depicted, although both contain SSR. Aim: We evaluated whether the heterogeneity, the type, and the amount of SSR might explain this contrasting finding. Materials, methods, and results: By ligand-binding the number of [125I-Tyr11]-SRIF-14 binding sites resulted comparable between the two tissues, whereas the number of [ 125I-Tyr3]-octreotide sites was significantly higher in the spleen (p2A mRNA in the spleen, whereas a significantly higher expression of SRIF and sst3 in the thymus. The highest density of sst2A in the spleen is in line with the in vivo uptake of [ 111In-DTPA-D-Phe1]-octreotide, which is considered a sst2-preferring ligand. The specificity is confirmed by the evidence that in vivo [111In-DT-PA-D-Phe1]-octreotide uptake can be abolished during chronic administration of "cold" octreotide. Immunohistochemistry confirmed a preferential expression of sst2A on microenvironmental cells and of sst3 on lymphoid cells. Conclusions: The heterogeneity of SSR expression and the higher SRIF content explain the lack of thymus visualization during scintigraphy, whereas thymic tumors, which do not express SRIF, are visualized. Apart from the affinity of the radioligand, also the efficacy of the internalization is crucial for the in vivo uptake, and both heterogeneity and SRIF content affect this process. These observations might have an important impact when interpretating in vivo visualization of SSR-positive lesions, and when treatment with novel SRIF analogs is considered.

KW - Receptor interaction

KW - Somatostatin

KW - Somatostatin receptors

KW - Spleen

KW - Thymus

UR - http://www.scopus.com/inward/record.url?scp=84863935925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863935925&partnerID=8YFLogxK

U2 - 10.3275/7871

DO - 10.3275/7871

M3 - Article

C2 - 21765239

AN - SCOPUS:84863935925

VL - 35

SP - 528

EP - 534

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 5

ER -